CymaBay Therapeutics
Dedicated to improving the lives of patients with liver diseases
32 employees · est. 1991 · Newark, United States
ENYO Pharma
Developing therapeutics for diseases with impaired kidney function
35 employees · est. 2014 · Lyon, France
CymaBay Therapeutics is the older company (1991 vs 2014).
Side-by-Side Comparison
| Metric | CymaBay Therapeutics | ENYO Pharma |
|---|---|---|
| Founded | ||
| Founded | 1991 older | 2014 |
| Headquarters | ||
| Headquarters | Newark, United States | Lyon, France |
| Employees | ||
| Employees | 32 | 35 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biopharma, Biotechnology |
| Funding Stage | ||
| Funding Stage | Acquired | Series C |
| Total Funding | ||
| Total Funding | $643.63M | $103.50M |
| Funding Rounds | ||
| Funding Rounds | 16 | 4 |
| Services | ||
| Services | Scientific Research, Development of Transformative Therapies, Clinical Trials Management, Global Medicine Distribution, Public Health Preparedness | Developing therapeutics for diseases with impaired kidney function |
| Target Customers | ||
| Target Customers | Healthcare Providers, Patients with Infectious Diseases, Cancer Patients, Pharmaceutical Distributors, Research Institutions | Patients with impaired kidney function, pharmaceutical companies, research institutions |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical Company, Clinical-stage, Liver Diseases, Autoimmune Liver Disease, Therapies, PPARδ Agonist, Primary Biliary Cholangitis, Investigational Products, Chronic Diseases, San Francisco Bay Area, Proprietary Medicines, Gout, Uric Acid, Phase 2 Studies, Metabolic Disease | Biopharmaceuticals, Therapeutics, Chronic Kidney Diseases, Rare Kidney Diseases, Liver Diseases, Infectious Diseases, Vonafexor, Intracellular Therapeutic Targets, Anti-virals, Drug Development, Phase 2 Trials, Research And Development, Inserm Patents, Viral Treatments, Global Leader |
| Website | ||
| Website | cymabay.com | enyopharma.com |
About CymaBay Therapeutics
CymaBay Therapeutics is a United States-based clinical-stage biopharmaceutical company, founded in 1991, with a focused mission, as expressed in their slogan: "Dedicated to improving the lives of patients with liver diseases." The company operates primarily within the Biopharma, Biotechnology, and P...
About ENYO Pharma
ENYO Pharma is a biopharmaceutical company that focuses on developing therapeutics for diseases with impaired kidney function. The company's lead compound, Vonafexor, is currently undergoing Phase 2 trials for Chronic Kidney Diseases (CKD), rare kidney diseases such as Alport syndrome, and liver dis...
We will tell you when either one moves
BounceWatch watches CymaBay Therapeutics and ENYO Pharma for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at CymaBay Therapeutics and ENYO Pharma — by email.
Frequently Asked Questions
Compare CymaBay Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at CymaBay Therapeutics on 11 Sep 2024, and ENYO Pharma on 11 Jun 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
